Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose titration study of sevelamer carbonate tablets TID in hyperphosphatemic chronic kidney disease patients not on dialysis
2005-003233-41Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2005
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sevelamer carbonate in chronic kidney disease (CKD) and hyperphosphatemia, sponsored by Sanofi. Primary endpoint: Change in serum phosphorus from baseline to Day 56 or early termination. Started Sep 2005; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
chronic kidney disease (CKD)hyperphosphatemia
Beyond the preview
Go deeper on 2005-003233-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003233-41.